Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
-
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
-
TRX Listing Launches on Binance.US, Advancing U.S. Market Access to TRON
-
Disconnected IT and OT Systems Undermine Utility Modernization Efforts, Reveals Info-Tech Research Group
-
Chronyx Studios Closed 1.5M USD Seed Round to Accelerate Growth and Expand Its Gaming Ecosystem
-
BVDW Launches IAB Diligence Platform, Powered by SafeGuard Privacy, in Germany with Nexida, Establishing New Standard for GDPR Compliance
-
Simpli5 Team Intelligence Platform Linked to Measurable Gains in Clinical Quality Across Healthcare Organizations
-
TGI Solar Power Group Inc. and MetaSense Inc. Advance Strategic Partnership to Build Integrated Workforce Intelligence Infrastructure for Next-Generation Industries
-
Action Target Announces Registration Is Open for 34th Annual Law Enforcement Training Camp (LETC)
-
SF Climate Week 2026 Kicks Off April 18 with More Than 60,000 Attendees, 650 Events, and Over 1,000 Speakers, including Al Gore, SF Mayor Daniel Lurie and Alex Honnold
-
Human eSources and Gratitude Initiative partner to support student success
-
HitPaw FotorPea V5.4.0 Launched: Unveiling AI Drawing, Image Enhancement, and Smarter Canvas for Next-Level Creativity
-
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
-
HelloNation Shares How to Choose an Indoor Golf Simulator Venue, Featuring Golf Shop & Simulator Expert David Klock
-
New DDOT Report Validates Warnings from Amy Witherite and Safety Advocates: Autonomous Vehicles Not Ready for Unrestricted Urban Deployment
-
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
-
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
-
Kairos Power Breaks Ground on Hermes 2 Demonstration Plant
-
EducationDynamics Named Reddit Gold Sales Certified Partner, Giving Institutions an Edge in the Channels Students Trust Most
-
AM Best Named a 2026 Top Workplace in the United States
-
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Ne
-
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
-
Creao AI Raises $10M to Build the Platform Where One Person Does the Work of a Team
-
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
-
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
-
SingleCell Biotechnology Presents Data at AACR Annual Meeting Demonstrating High-Throughput Single-Cell Assay Linking Clonal Growth Phenotypes to Molecular Profiles
-
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
-
Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small
-
Crestwood Advisors Named Once Again to USA TODAY’s 2026 Best Financial Advisory Firms List
-
Salubris Biotherapeutics Presents Phase 1/2 Dose Escalation and Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Annual Meeting
-
Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
-
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
-
Orum Therapeutics Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Imp
-
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026
-
Akamis Bio Announces Encouraging Preliminary Results from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
-
OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform
-
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
-
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection
-
NEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate Pipeline
-
Study Finds AI Medical Diagnosis Errors Exceed 80%
-
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
-
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
-
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
-
Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026
-
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
-
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
-
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
-
New ACP Breast Cancer Screening Guidelines Are a Step Backward that May Cost Lives
-
Cegedim: Release of its 2025 Universal Registration Document
-
Marcus & Millichap Closes Two Westside Los Angeles Multifamily Sales at Record Value

